CGEM
Price:
$17.98
Market Cap:
$1.04B
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific...[Read more]
Industry
Biotechnology
IPO Date
2021-01-08
Stock Exchange
NASDAQ
Ticker
CGEM
According to Cullinan Oncology, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.88. This represents a change of 33.37% compared to the average of -4.41 of the last 4 quarters.
The mean historical PE Ratio of Cullinan Oncology, Inc. over the last ten years is -20.61. The current -5.88 PE Ratio has changed 2.75% with respect to the historical average. Over the past ten years (40 quarters), CGEM's PE Ratio was at its highest in in the June 2022 quarter at 0.82. The PE Ratio was at its lowest in in the March 2021 quarter at -6247.13.
Average
-20.61
Median
-17.32
Minimum
-64.96
Maximum
4.28
Discovering the peaks and valleys of Cullinan Oncology, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 169.14%
Maximum Annual PE Ratio = 4.28
Minimum Annual Increase = -164.52%
Minimum Annual PE Ratio = -64.96
Year | PE Ratio | Change |
---|---|---|
2023 | -2.76 | -164.52% |
2022 | 4.28 | -140.77% |
2021 | -10.51 | -58.95% |
2020 | -25.60 | -60.60% |
2019 | -64.96 | 169.14% |
The current PE Ratio of Cullinan Oncology, Inc. (CGEM) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.00
5-year avg
-19.91
10-year avg
-20.61
Cullinan Oncology, Inc.’s PE Ratio is less than Bolt Biotherapeutics, Inc. (-0.37), greater than Day One Biopharmaceuticals, Inc. (-7.39), less than Lyra Therapeutics, Inc. (-0.18), less than Autolus Therapeutics plc (-4.55), less than Sana Biotechnology, Inc. (-4.82), greater than Olema Pharmaceuticals, Inc. (-6.07), less than aTyr Pharma, Inc. (-2.33), less than Zentalis Pharmaceuticals, Inc. (-1.08), less than Century Therapeutics, Inc. (-0.91), greater than Edgewise Therapeutics, Inc. (-14.14), less than C4 Therapeutics, Inc. (-3.44), less than Mineralys Therapeutics, Inc. (-4.63), less than Talaris Therapeutics, Inc. (-0.20), less than Adicet Bio, Inc. (-0.98), less than Vor Biopharma Inc. (-0.53), less than Lyell Immunopharma, Inc. (-1.42), less than Monte Rosa Therapeutics, Inc. (-3.11), less than Theseus Pharmaceuticals, Inc. (-3.19), greater than Revolution Medicines, Inc. (-13.31),
Company | PE Ratio | Market cap |
---|---|---|
-0.37 | $24.78M | |
-7.39 | $1.25B | |
-0.18 | $17.85M | |
-4.55 | $1.07B | |
-4.82 | $1.12B | |
-6.07 | $677.46M | |
-2.33 | $131.12M | |
-1.08 | $210.48M | |
-0.91 | $123.69M | |
-14.14 | $1.64B | |
-3.44 | $374.42M | |
-4.63 | $558.43M | |
-0.20 | $116.44M | |
-0.98 | $121.95M | |
-0.53 | $62.11M | |
-1.42 | $299.52M | |
-3.11 | $349.21M | |
-3.19 | $181.50M | |
-13.31 | $6.99B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cullinan Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cullinan Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cullinan Oncology, Inc.'s PE Ratio?
How is the PE Ratio calculated for Cullinan Oncology, Inc. (CGEM)?
What is the highest PE Ratio for Cullinan Oncology, Inc. (CGEM)?
What is the 3-year average PE Ratio for Cullinan Oncology, Inc. (CGEM)?
What is the 5-year average PE Ratio for Cullinan Oncology, Inc. (CGEM)?
How does the current PE Ratio for Cullinan Oncology, Inc. (CGEM) compare to its historical average?